Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · IEX Real-Time Price · USD
7.96
-0.35 (-4.21%)
At close: Jul 19, 2024, 4:00 PM
7.99
+0.03 (0.38%)
Pre-market: Jul 22, 2024, 7:28 AM EDT
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for IOVA stock have an average target of 25.7, with a low estimate of 19 and a high estimate of 34. The average target predicts an increase of 222.86% from the current stock price of 7.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IOVA stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 6 | 5 | 5 | 4 | 4 | 4 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 11 | 11 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +302.01% | Jun 28, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $25 → $23 | Buy | Maintains | $25 → $23 | +188.94% | Jun 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +302.01% | Jun 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +302.01% | May 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +302.01% | May 24, 2024 |
Financial Forecast
Revenue This Year
164.41M
from 1.19M
Increased by 13,727.59%
Revenue Next Year
451.06M
from 164.41M
Increased by 174.35%
EPS This Year
-1.40
from -1.89
EPS Next Year
-0.74
from -1.40
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 261.1M | 651.4M | 1.2B | 1.6B | 1.8B |
| Avg | 164.4M | 451.1M | 728.6M | 1.1B | 1.4B |
| Low | 32.5M | 127.9M | 302.7M | 514.5M | 725.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 21,863.0% | 296.2% | 157.8% | 115.8% | 65.9% |
| Avg | 13,727.6% | 174.4% | 61.5% | 51.7% | 26.8% |
| Low | 2,636.4% | -22.2% | -32.9% | -29.4% | -34.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.14 | -0.01 | 1.27 | 1.46 | 2.22 |
| Avg | -1.40 | -0.74 | 0.03 | 0.54 | 1.23 |
| Low | -1.75 | -1.49 | -0.93 | -0.37 | 0.29 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 4,669.6% | 311.4% |
| Avg | - | - | - | 1,660.0% | 128.2% |
| Low | - | - | - | - | -45.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.